Iq Ai Ltd - IQAIF STOCK NEWS

IQ-AI Limited (OTCQB:IQAIF) has received orphan drug designation (ODD) from the FDA for gallium maltolate (GaM) aimed at treating glioblastoma multiforme (GBM). This designation supports the ongoing Phase I clinical trial at the Medical College of Wisconsin, which assesses GaM's safety and tolerability. Orphan designation offers several advantages including tax credits, grant opportunities, and seven years of market exclusivity post-approval. CEO Trevor Brown highlighted that this milestone brings the potential for GaM as a treatment option for GBM closer to realization.

Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF), has submitted an FDA 510(k) application for IB Zero G, an AI software that eliminates the need for gadolinium-based contrast agents in routine MRI exams. This zero-dose technology aims to enhance patient comfort and safety, particularly for those with kidney issues or gadolinium retention concerns. The submission marks a pivotal moment in the global GBCA market, potentially transforming radiology practices by mitigating supply chain vulnerabilities highlighted by recent iodinated contrast agent shortages.

Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF), highlights a study published in the American Journal of Neuroradiology showing that its DSC-MRI technology effectively distinguishes between tumor and non-tumor tissues in metastatic brain tumors treated with stereotactic radiosurgery. This study, led by Dr. Michael Iv, demonstrates IB Neuro's superior imaging capability compared to traditional methods. With brain metastases expected to rise, the findings validate the development of IB Trax software, enhancing monitoring and accuracy for neuroradiologists.

A novel therapy for glioblastoma, developed at the Medical College of Wisconsin, has progressed to clinical trials. This oral treatment, gallium maltolate (GaM), shows promising results in preclinical studies by significantly slowing tumor growth. Led by Dr. Christopher Chitambar, the trial aims to evaluate GaM's effectiveness against this aggressive brain cancer, with an expected completion date of December 2025. The trial is sponsored by Imaging Biometrics, a subsidiary of IQ-AI Ltd., supported by grants from the Musella Brain Tumor Foundation and MCW Cancer Center.

IQ-AI Limited (OTCQB:IQAIF) has opened enrollment for its Phase I clinical trial of oral gallium maltolate (GaM), aimed at treating glioblastoma multiforme (GBM). Led by Dr. Jennifer Connelly and Dr. Christopher Chitambar at the Medical College of Wisconsin, the trial seeks to establish the optimal dose of GaM. Motivated by preclinical results showing tumor growth inhibition and increased survival rates, the project faced some delays due to the qualification of a new encapsulation supplier, now resolved. CEO Trevor Brown expressed enthusiasm about the trial's commencement.

Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF), announced that a review by international experts recognized dynamic susceptibility contrast (DSC) MRI as the most clinically validated method for assessing treatment response in high-grade brain tumors. Published in Frontiers in Oncology, the review highlighted the company's proprietary technology, IB Neuro, which enhances MRI data analysis through standardized relative cerebral blood volume (sRCBV) mapping. This capability promotes consistency in MRI scans, independent of various factors.

Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF), reported its most successful year with revenues exceeding $700K, more than double from the previous year. Key highlights include the rollout of a Phase I clinical trial and the anticipation of filing a 510(k) application with the FDA for its innovative products. The company's unique IB Clinic software shows strong adoption rates, promising a significant impact on brain tumor diagnostics. Collaboration with esteemed partners continues to grow as they gear up for an even more successful 2022.

IQ-AI Limited (OTCQB:IQAIF) announced a Data Use Agreement with St. Jude Children's Hospital to enhance the development of its IB Zero G artificial intelligence technology. This agreement allows Imaging Biometrics access to pediatric imaging datasets, crucial for refining AI models. The technology aims to eliminate the need for gadolinium-based contrast agents in MRI exams, addressing safety concerns linked to their use. The FDA 510(k) application for IB Zero G is set for late Q1 2022, which may potentially accelerate its commercialization.

IQ-AI Limited announced that the University of Texas MD Anderson Cancer Center has purchased an annual subscription for its IB Clinic software, designed to enhance brain tumor assessment through automated processing of magnetic resonance images. This installation will integrate IB Neuro and IB DCE software to streamline workflows, providing quantitative maps for diagnostic interpretation. The purchase underscores IQ-AI's growth, as highlighted by a recent record year. MD Anderson, recognized as the top cancer center in the USA, will leverage this technology to improve patient outcomes.